Crystec’s mSAS® technology shortlisted for CPhI Award

CrystecPharma are delighted to have been shortlisted for the CPhI Excellence in Pharma Awards 2021, in recognition of our industry-leading position in enabling the accelerated development of optimised inhaled therapeutics.

Crystec’s mSAS® (modified Supercritical Anti-Solvent) technology offers unique advantages for targeting desirable properties for inhalation powders so they can be readily administered from simple, off-the-shelf devices, and in patients with a compromised respiratory system. By designing performance into particles, impressive levels of lung deposition can be achieved while maintaining simple formulations, eliminating the need for complex device development programmes. Overall, by applying mSAS® in the development of inhaled therapies, high quality, innovative and strongly performing products can be developed under vastly accelerated timelines, with rapid transition from concept laboratory studies to manufacture of GMP material at commercial scale.

The winners of the competition will be announced during an awards reception at CPhI Milan on Tuesday 9th November. More about the awards, including a full list of finalists, can be found here.

If you would like to hear more about Crystec’s mSAS® technology and how it can be applied to accelerate the development of optimised inhaled products, please get in touch!